IPSC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Century Therapeutics Inc (IPSC) is not a good buy for a beginner investor with a long-term focus at this time. The company's financial performance is weak, with significant revenue and net income declines. Insider and hedge fund selling trends indicate negative sentiment, and technical indicators do not suggest a strong entry point. While the company's pipeline holds potential, there are no immediate positive catalysts or strong trading signals to justify a buy decision.
The MACD is negatively expanding, RSI is at 27.184 (neutral zone), and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 2.068), but there is no strong technical signal for a buy.
Analyst TD Cowen initiated coverage with a Buy rating, citing the company's promising pipeline, particularly CNTY-813 for type 1 diabetes.
Hedge funds and insiders are selling heavily, with insider selling increasing by 4466.89% over the last month. The company's financials show a complete revenue drop and significant net income decline. No recent news or congress trading data is available to support a positive sentiment.
In Q4 2025, revenue dropped to 0 (-100% YoY), net income dropped to -$19.17M (-46.85% YoY), and EPS dropped to -0.22 (-47.62% YoY). Gross margin remained flat at 100%.
TD Cowen initiated coverage with a Buy rating, highlighting the company's pipeline potential but did not provide a price target.
